Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075738 | 0.92 | POLB (0.52) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19084008 | 0.84 | L3MBTL1 (0.51) | PDE4APDE4BPDE4CPDE4DUTS2R | |
| SCHEMBL17946308 | 0.84 | RAB9A (0.51) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17946099 | 0.82 | MAPT (0.51) | POLBUTS2RKCNH2CACNA1ISLC5A7 | |
| SCHEMBL19075730 | 0.75 | NPC1 (0.48) | PDE4APDE4BPDE4CPDE4DUTS2R | |
| SCHEMBL17946117 | 0.74 | UTS2R (0.55) | POLBUTS2RMEN1KMT2ACCR3 | |
| SCHEMBL12437926 | 0.74 | OPRK1 (0.45) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19083721 | 0.73 | PDE4D (0.74) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL19075747 | 0.73 | PDE4A (0.61) | POLBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2392400 | 0.72 | CCR3 (0.50) | POLBPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | POLB 2801/4885PDE4A 449/4885PDE4B 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.